Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...
As of the third quarter of 2023, Invitae had already tallied a net loss of more than $1.3 billion for the year, with cash burn of $311 million as of Sept. 30 and just under $265 million left in cash ...
Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...
Invitae (NYSE: NVTA) has been one of the most beaten-up stocks this year, falling more than 70% thus far (the S&P 500 has declined by only 10% over the same period). Significant losses and a growth ...
The company will offer up to 12.8 million shares of common stock that could fetch up to $57.5 million in gross proceeds. Today, Invitae announced that each share will be offered at $4.50, which is ...
— The transaction contributes to Invitae's cash runway and includes a strategic supply partnership to support the growth of Invitae Personalized Cancer Monitoring™ (PCM) services — SAN FRANCISCO, Dec.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results